209 related articles for article (PubMed ID: 35636078)
21. Nivolumab in Squamous Cell Carcinomas of the Head and Neck (SCCHN): A Real-world Outcome Study in Ontario, Canada.
Zereshkian A; Shafi R; Pond GR; Hotte SJ
J Immunother; 2024 May; 47(4):123-127. PubMed ID: 38230590
[TBL] [Abstract][Full Text] [Related]
22. Analysis of the benefit of salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck.
Reverdy T; Varnier R; de Talhouët S; Duplomb S; Bruyas A
Oral Oncol; 2023 Oct; 145():106533. PubMed ID: 37562096
[TBL] [Abstract][Full Text] [Related]
23. Outcome of chemotherapy following nivolumab treatment for recurrent and/or metastatic head and neck squamous cell carcinoma.
Wakasaki T; Yasumatsu R; Uchi R; Taura M; Matsuo M; Komune N; Nakagawa T
Auris Nasus Larynx; 2020 Feb; 47(1):116-122. PubMed ID: 31128940
[TBL] [Abstract][Full Text] [Related]
24. Nivolumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Retrospective Tertiary Centre's Real-World Experience.
Du YJ; Fu R; Levinsky JT; Kamalraj P; Chan KKW; Parmar A; Eskander A; Smoragiewicz M
Curr Oncol; 2023 Sep; 30(10):8928-8935. PubMed ID: 37887545
[TBL] [Abstract][Full Text] [Related]
25. A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator's choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141.
Kiyota N; Hasegawa Y; Takahashi S; Yokota T; Yen CJ; Iwae S; Shimizu Y; Hong RL; Goto M; Kang JH; Sum Kenneth Li W; Ferris RL; Gillison M; Namba Y; Monga M; Lynch M; Tahara M
Oral Oncol; 2017 Oct; 73():138-146. PubMed ID: 28939066
[TBL] [Abstract][Full Text] [Related]
26. Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab.
Hirai Y; Kurihara K; Sano D; Inamo M; Takahashi H; Ichikawa Y; Oridate N
In Vivo; 2023; 37(6):2687-2695. PubMed ID: 37905649
[TBL] [Abstract][Full Text] [Related]
27. Age-based efficacy and safety of nivolumab for recurrent or metastatic head and neck squamous cell carcinoma: A multicenter retrospective study.
Kondo T; Okamoto I; Sato H; Koyama N; Fushimi C; Okada T; Masubuchi T; Miura K; Matsuki T; Yamashita T; Omura G; Takahashi H; Tsukahara K
Asia Pac J Clin Oncol; 2020 Dec; 16(6):340-347. PubMed ID: 32573033
[TBL] [Abstract][Full Text] [Related]
28. Real-World Experience of Immunotherapy from India in Recurrent Squamous Cell Carcinoma of Head and Neck Cancer.
Abbas W; Gupta S; Goel V; Rao RR; Pankaj P; Tripathi D; Patil PP; Popli S
South Asian J Cancer; 2021 Apr; 10(2):72-75. PubMed ID: 34568218
[No Abstract] [Full Text] [Related]
29. Therapeutic effect of Nivolumab for advanced / recurrent temporal bone squamous cell carcinoma.
Noda T; Komune N; Yasumatsu R; Tsuchihashi NA; Tamae A; Matsumoto N; Sato K; Uchi R; Koike K; Wakasaki T; Tanaka R; Nakagawa T
Auris Nasus Larynx; 2020 Oct; 47(5):864-869. PubMed ID: 32446629
[TBL] [Abstract][Full Text] [Related]
30. CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.
Gillison ML; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Li L; Ferris RL
Oncologist; 2018 Sep; 23(9):1079-1082. PubMed ID: 29866947
[TBL] [Abstract][Full Text] [Related]
31. A Q-TWiST Analysis Comparing Nivolumab and Therapy of Investigator's Choice in Patients with Recurrent/Metastatic Platinum-Refractory Squamous Cell Carcinoma of the Head and Neck.
Cocks K; Contente M; Simpson S; DeRosa M; Taylor FC; Shaw JW
Pharmacoeconomics; 2019 Aug; 37(8):1041-1047. PubMed ID: 30972702
[TBL] [Abstract][Full Text] [Related]
32. Effect of tumor burden and growth rate on treatment outcomes of nivolumab in head and neck cancer.
Suzuki C; Kiyota N; Imamura Y; Rikitake J; Sai S; Koyama T; Hyogo Y; Nagatani Y; Funakoshi Y; Toyoda M; Otsuki N; Nibu KI; Minami H
Int J Clin Oncol; 2020 Jul; 25(7):1270-1277. PubMed ID: 32277393
[TBL] [Abstract][Full Text] [Related]
33. Impact of previous nivolumab treatment on the response to taxanes in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Guiard E; Clatot F; Even C; Perréard M; Abdeddaim C; Johnson A; Vauléon E; Rambeau A
Eur J Cancer; 2021 Dec; 159():125-132. PubMed ID: 34743067
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab versus investigator's choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age.
Saba NF; Blumenschein G; Guigay J; Licitra L; Fayette J; Harrington KJ; Kiyota N; Gillison ML; Ferris RL; Jayaprakash V; Li L; Brossart P
Oral Oncol; 2019 Sep; 96():7-14. PubMed ID: 31422216
[TBL] [Abstract][Full Text] [Related]
35. Antibiotics May Interfere with Nivolumab Efficacy in Patients with Head and Neck Squamous Cell Carcinoma.
Ueta R; Imai H; Saijo K; Kawamura Y; Kodera S; Komine K; Ouchi K; Kasahara Y; Taniguchi S; Yoshida Y; Sasaki K; Shirota H; Takahashi M; Ishioka C
Oncology; 2024; 102(3):252-259. PubMed ID: 37708868
[TBL] [Abstract][Full Text] [Related]
36. Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Economopoulou P; Kotsantis I; Papaxoinis G; Gavrielatou N; Anastasiou M; Pantazopoulos A; Kavourakis G; Gkolfinopoulos S; Panayiotides I; Delides A; Psyrri A
Oral Oncol; 2020 Dec; 111():105013. PubMed ID: 32977184
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States.
Haddad R; Cohen EEW; Venkatachalam M; Young K; Singh P; Shaw JW; Korytowsky B; Abraham P; Harrington KJ
J Med Econ; 2020 May; 23(5):442-447. PubMed ID: 31928375
[No Abstract] [Full Text] [Related]
38. Multicenter retrospective study of nivolumab for recurrent/metastatic oral squamous cell carcinoma.
Yamakawa N; Umeda M; Yoshii Y; Mitsudo K; Noguchi M; Kusukawa J; Katakura A; Nakayama H; Sasaki M; Noguchi T; Ueda M; Bukawa H; Yagihara K; Horie A; Miyazaki A; Chikazu D; Tomihara K; Mishima K; Otsuru M; Asoda S; Fujiwara S; Ohyama Y; Kurita H; Kawamata H; Fukuda M; Shintani Y; Kobayashi T; Kanno T; Oh-Iwa I; Kawano K; Yamashita Y; Kobayashi W; Ohiro Y; Uzawa K; Ota Y; Kirita T
Oral Dis; 2024 Mar; 30(2):247-258. PubMed ID: 36519515
[TBL] [Abstract][Full Text] [Related]
39. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington K; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Iglesias Docampo LC; Haddad R; Rordorf T; Kiyota N; Tahara M; Monga M; Lynch M; Geese WJ; Kopit J; Shaw JW; Gillison ML
N Engl J Med; 2016 Nov; 375(19):1856-1867. PubMed ID: 27718784
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of chemotherapy after progression with nivolumab in squamous cell carcinoma of the head and neck.
Suzuki S; Toyoma S; Tomizawa H; Yamada T; Iikawa N; Shiina K; Saito H; Koizumi K; Kawasaki Y; Yamada T
Auris Nasus Larynx; 2020 Jun; 47(3):485-488. PubMed ID: 31248647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
